105results about "Complement proteins" patented technology

An engineered polypeptide for use in treating age-related macular degeneration (AMD) comprising FHL-1 engineered variant peptides, compositions including these engineered polypeptides and methods of using them. Further, wherein polypeptides include a linker domain separating the first peptide sequence from the second peptide sequence, a first junction region between the first peptide sequence and the linker domain and a second junction region between the second peptide sequence and the linker domain.

The invention relates to a recombinant complement protein and application thereof in preparation of anti-leukemia drugs, and belongs to the technical field of biological medicines. The invention discloses a method for treating acute leukemia by single drug, namely injecting recombinant C1QBP protein, which has a remarkable effect on treating acute leukemia, can be used for remarkably inhibiting proliferation of leukemia cells in marrow, spleen and peripheral blood of a hematopoietic system and also inhibiting infiltration of the leukemia cells in extramedullary organs (skin and the like), so that the whole-body tumor load is reduced, and the curative effect of treating acute leukemia is improved. The lifetime of leukemia mice is obviously prolonged. The recombinant C1QBP protein is combined with a clinical first-line chemotherapy regimen for use, has a synergistic effect, has a stronger effect of inhibiting leukemia cell proliferation compared with a single chemotherapy drug, can significantly prolong the lifetime of leukemia mice, and plays a role in reducing toxicity and enhancing efficacy. The invention proves that the complement C1Q binding protein has the effect of treating leukemia for the first time, provides a preparation method and a drug combination scheme, and has relatively high clinical transformation prospect and application value.

The present invention provides antagonizing antibodies that bind to complement factor D (CFD), conjugates thereof, and methods of using same. The anti-CFD antibodies can be used therapeutically alone or in combination with other therapeutics to treat age related macular degeneration and other diseases.

The invention provides plasmin-targeted complement C3 derived anticoagulant polypeptide and application thereof, and belongs to the technical field of biological medicine. The present invention provides a complement C3-derived anticoagulant polypeptide (C3-HK10) and a modified peptide (C3-moHK10), which reduce nerve injury by enhancing the activity of plasmin in degrading fibrin thrombus and promoting the production of matBDNF (matured brain-derived neurotrophic factor), thereby protecting a host from dual threats of inflammatory thrombosis and neurological dysfunction, and also provides a method for preparing the anticoagulant polypeptide (C3-HK10) and a modified peptide (C3-moHK10). And good safety is shown. In conclusion, it is found for the first time that the complement C3 polypeptides C3-HK10 and C3-moHK10 have the characteristic of promoting plasmin activity, have the functions of inhibiting inflammation, thrombus and ischemic cerebral apoplexy injury and relieving nerve injury, and have the potential of becoming anti-inflammatory, thrombus and stroke treatment and neurological function drugs.

The present invention relates to a chimeric construct comprising i) an interleukin 2 (IL2) moiety and ii) the beta chain of C4b-binding protein (C4BPβ) or at least one fragment or functional variant thereof capable of forming a dimeric protein.

The invention relates to generally to the field of oncology. Provided herein is a method for detecting for detecting and classifying nasopharyngeal cancer.

The present application relates to a fusion protein of a biopolymer target-specific complement inhibitor, comprising: (i) the extracellular domain of CRIg, (ii) a complement regulatory domain, and (iii) an enhancer domain, as well as methods for producing and using the fusion protein, and pharmaceutical compositions containing the fusion protein. The fusion protein not only has significant targeted complement inhibitory effects, but can also promote increased drug formation and / or production for the treatment and prevention of various human diseases associated with abnormal complement activation.

The disclosure provides modified complement 3d (C3d), compositions containing modified C3d, and methods of using the C3d compositions to treat diseases and disorders, for examples, disease and disorders characterized by evasion of immune surveillance and / or tumor-induced immunosuppression (e.g., multiple myeloma and other plasma cell malignancies).

This invention provides expressible polynucleotides, which can express a target protein or polypeptide. Synthetic mRNA constructs for producing a protein or polypeptide can contain one or more 5' UTRs, where a 5' UTR may be expressed by a gene of a plant. In some embodiments, a 5 UTR may be expressed by a gene of a member of Arabidopsis genus. The synthetic mRNA constructs can be used as pharmaceutical agents for expressing a target protein or polypeptide in vivo.

An isolated antigen binding protein, which includes at least one CDR of a heavy chain variable region and at least one CDR of a light chain variable region and a method to encode an isolated nucleic acid molecule. A vector with the nucleic acid molecule. A cell with the nucleic acid molecule. A pharmaceutical composition with the isolated antigen binding protein. A method for preventing, alleviating or treating a C5-related disease or disorder. A method for detecting C5 in a sample.

The present invention relates to an antibody that specifically binds to complement C5, and a fusion protein thereof. The present invention also relates to a polynucleotide encoding the antibody or the fusion protein, an expression vector, and a host cell, and a pharmaceutical composition thereof, and a method and use for treating C5 protein-related diseases.

The invention relates to anti-C5 antibody combinations and uses thereof. The present invention relates to a combination of an anti-C5 antibody and an antigen-binding fragment, which combination has been determined to have higher activity relative to a single anti-C5 antibody or fragment. The combination comprises an anti-C5 antibody and an antigen binding fragment that do not compete with each other for binding to C5. Bispecific antibodies comprising antigen binding domains that do not compete and / or bind to the same epitope on C5 are also provided. Provided herein are compositions and methods of treatment relating to such anti-C5 combinations and bispecific antibodies.

A protein polymer and a production process therefor. The protein polymer is obtained by means of stimulating MSCs, lysing same, and separating and purifying same. The protein polymer has a strong capability to repair oxidative damage, and thus can reduce the range of cerebral infarction, improve neural functions, inhibit the level of neuroinflammation, and increase the number of surviving neurons.

The disclosure relates to a non-human animal that express a human or chimeric (e.g., humanized) CFB protein and methods of use thereof. The disclosure further provides a non-human animal genome, a humanized CFB gene, and cells, tissues, organs, or non-human animals comprising the non-human animal genome or the humanized CFB gene. The non-human animals obtained in present disclosure successfully express human or humanized CFB protein, which can be cleaved by CFD, bind to C3b, and exert functions similar to those in the human. Moreover, the non-human animals obtained in present disclosure maintain intact renal function status and normal blood biochemical parameters. Notably, these non-human animals do not result in the potential pathologies observed in some other transgenic mice known in the art.

Present invention relates to novel antibodies and their use in an improved method of determining and detecting C4d.

The present invention is related to a C5a binding agent for use in a method for treating and / or preventing a disease in a subject, wherein the disease is associated with or caused by C5a.

The invention provides application of C1q complement protein in preparation of an element for detecting Abeta42 protein, a chip for detecting the Abeta42 protein and application of the chip. The C1q complement protein is used as an element for specifically recognizing the Abeta42 protein, the C1q complement protein can be fixed on the chip body, and the obtained chip can be used for preparing a specific element, such as a biosensor. Compared with the prior art, when the biosensor based on the dual-polarization interference technology is used for detecting the Abeta42 protein, synthesis of a complex nano material or design of a complex signal transduction pathway is not needed, and the biosensor has the advantages of being easy and convenient to operate, high in selectivity and high in renewability.

An isolated polynucleotide comprising a nucleotide sequence encoding a codon-optimised Complement Factor I (CFI).

Hydrochloride salt forms of synthetic C-terminal peptide analogs of C5a, which are response selective agonists of C5aR-bearing antigen presenting cells. Methods of inducing an immune response in a subject by administering such peptide analogs alone or in combination with other active agents are also disclosed.

The present invention relates to the treatment of cancer and to the prevention of cancer growth and / or metastasis. In particular, the invention relates to cellular and acellular vaccines containing C3d, a proteolytic product of complement (C3), and methods of enhancing a host immune response (e.g., a T cell mediated immune response) against cancers using same. Compositions and methods of the invention find use, alone or in conjunction with other cancer therapies, in treating lymphoma and / or cancers that develop and / or persist by evading host immune surveillance and / or responses (e.g., T-cell mediated immune responses). Compositions and methods of the invention find use in both clinical and research settings, for example, within the fields of biology, immunology, medicine, and oncology.

The present invention relates to a multi-domain polypeptide comprising (i) a first complement control protein repeat (CCP)-comprising domain being a convertase decay accelerating domain for convertases of the classical and alternative pathways of complement activation, (ii) a host cell recognition domain, and (iii) a second CCP-comprising domains with cofactor activity. The present invention further relates to a polynucleotide encoding said multi-domain polypeptide, to a vector comprising said polynucleotide, and to a host cell comprising said polynucleotide and / or said vector. Further, the present invention relates to the multi-domain polypeptide, the polypeptide, and the vector for use in medicine and for treating and / or preventing inappropriate complement activation and / or a disease having inappropriate complement activation as a symptom. Moreover, the present invention relates to methods and uses related to multi-domain polypeptide, the polypeptide, and the vector.

An AAV vector comprising a nucleotide sequence encoding Factor I or a fragment or derivative thereof.

In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.

A promoter comprising (i) a nucleotide sequence having at least 70% identity to SEQ ID NO: 4 or 17 and wherein the promoter has a length of about 1.1 kb or less.

A synapse surgical tool for selectively removing or ablating a postsynaptic terminal from a neuron, the method comprising: delivering an expression vector comprising a nucleic acid encoding a fusion protein comprising an N-terminal domain comprising an activated glial receptor binding domain; and a C terminal domain comprising a transmembrane domain of postsynaptic protein; expressing the fusion protein so that the activated glial receptor binding domain is localized to a synaptic cleft of the postsynaptic terminal of the neuron; and contacting the neuron with an activated microglial cell so that the activated microglial binds to the activated glial receptor binding domain and selectively ablates the postsynaptic terminal of the neuron.

Disclosed herein are fusion polypeptides comprising: (i) a fragment antigen comprising an epitope of a target protein antigen; and (ii) a complement binding polypeptide. The disclosure also provides fusion polynucleotides (e.g., mRNA) encoding the same. Also disclosed herein are methods of making and using the fusion polypeptides and fusion polynucleotides of the present disclosure.

A fusion protein is provided having a structure A-L-B, wherein: A comprises a sequence that has at least 90% similarity to SEQ ID NO :1; L comprises a linker or a chemical bond; B comprises a sequence that has at least 90% similarity to SEQ ID NO:2. Also provided are medical devices at least partially coated with the fusion protein and uses of the fusion protein.

The present invention relates to a method for stabilizing a fast decay component C3bBb complex of a bypass pathway of a complement system as well as a stabilized C3bBb complex and its use.

The described invention provides a method for treating a complement disorder such as age-related macular degeneration (AMD) in a subject, comprising administering a pharmaceutical composition to an affected eye of the subject by ocular injection, wherein the composition comprises a nucleic acid encoding a soluble CD59 (sCD59) protein operably linked to a promoter, wherein the nucleic acid encoding sCD59 is packaged into a delivery vector and administration results in expression and secretion of the sCD59 protein by cells of the affected eye, wherein expression results in treatment of the affected cells in the diseased eye.

The present disclosure features methods, cells or cell lines, and compositions for increasing the amount of products, e.g., proteins, produced by a cell or cell line by reducing the level of a non-essential endogenous protein.